Los Angeles Capital Management’s Sage Therapeutics SAGE Stock Holding History

Los Angeles Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,501	Closed	-$57K	–	1207
2024 Q4	$57K	Hold	10,501	–	–	﹤0.01%	1095
2024 Q3	$75.8K	Hold	10,501	–	–	﹤0.01%	1147
2024 Q2	$114K	Sell	10,501 -4,847	-32%	-$62.1K	﹤0.01%	1152
2024 Q1	$288K	Hold	15,348	–	–	﹤0.01%	1020
2023 Q4	$333K	Buy	+15,348	New	+$304K	﹤0.01%	986
2022 Q2	–	Sell	-13,030	Closed	-$431K	–	1443
2022 Q1	$431K	Buy	+13,030	New	+$490K	﹤0.01%	1098
2019 Q2	–	Sell	-8,321	Closed	-$1.32M	–	1414
2019 Q1	$1.32M	Buy	+8,321	New	+$1.21M	0.01%	767
2018 Q4	–	Sell	-1,570	Closed	-$222K	–	1367
2018 Q3	$222K	Sell	1,570 -87,686	-98%	-$13.5M	﹤0.01%	1309
2018 Q2	$14M	Buy	89,256 +58,069	+186%	+$9.12M	0.08%	289
2018 Q1	$5.02M	Buy	31,187 +28,087	+906%	+$4.77M	0.03%	429
2017 Q4	$511K	Sell	3,100 -350	-10%	-$33.9K	﹤0.01%	1044
2017 Q3	$215K	Buy	+3,450	New	+$271K	﹤0.01%	1238
2016 Q3	–	Sell	-6,890	Closed	-$208K	–	1272
2016 Q2	$208K	Buy	+6,890	New	+$230K	﹤0.01%	1151

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Los Angeles Capital Management's SAGE Position: Q1 2025 in Review

Los Angeles Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 10,501 shares — an estimated $57K sold.

Los Angeles Capital Management first reported a position in SAGE in Q2 2016 and held it in 13 quarters. The position peaked at $14M in Q2 2018. 197 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

Los Angeles Capital Management reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
Los Angeles Capital Management sold 10,501 Sage Therapeutics shares in Q1 2025, an estimated $57K.
Los Angeles Capital Management first reported a position in Sage Therapeutics in Q2 2016 and held it in 13 quarters.
Los Angeles Capital Management's Sage Therapeutics position peaked at $14M in Q2 2018.
197 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Los Angeles Capital Management's 13F filing for Q1 2025, filed 5 May 2025.